Shaheen Wirk - 15 Apr 2025 Form 4/A - Amendment Insider Report for Tvardi Therapeutics, Inc. (TVRD)

Reporting relationship: Director
Issuer ticker: TVRD
Reported as of: 15 Apr 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 02 May 2025, 18:12:20 UTC
Original report date: 17 Apr 2025
Prior SEC filing: 06 Jan 2025
Next SEC filing: 21 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Dan Conn, Attorney- in-Fact

Key filing fact

Shaheen Wirk filed Form 4/A - Amendment for Tvardi Therapeutics, Inc. (TVRD) on 02 May 2025.

Key facts

This page summarizes Shaheen Wirk's Form 4/A - Amendment filing for Tvardi Therapeutics, Inc. (TVRD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 May 2025, 18:12.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002050227 Primary reporting owner

Wirk Shaheen

Relationship: Director
Address: C/O TVARDI THERAPEUTICS, INC., 3 SUGAR CREEK CTR BLVD, STE 525, SUGAR LAND
Signature: /s/ Dan Conn, Attorney- in-Fact
Signature date: 02 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVRD transaction

Common Stock

Award

Transaction value
Shares: +176,030
Change %
Price
Shares after: 176,030
Date: 15 Apr 2025
Ownership: Palkon Holdings, LLC
Footnotes: F1, F2, F3, F4

TVRD transaction

Common Stock

Award

Transaction value
Shares: +263,164
Change %
Price
Shares after: 263,164
Date: 15 Apr 2025
Ownership: Palkon TT Holdings, LLC
Footnotes: F1, F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The initial Form 4 inadvertently listed an incorrect transaction code.

Footnote F2

Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.

Footnote F3

Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.

Footnote F4

The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein.

Footnote F5

Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.